About Mitogen-activated protein kinase 3
Mitogen-activated protein kinase 3 (MAPK3) is a protein
from Homo sapiens identified by UniProt accession
P27361, 379 residues long.
MolForge cross-references it against 0 known binders and
1,200 disease associations.
Target properties
| Protein name | Mitogen-activated protein kinase 3 |
| UniProt accession | P27361 |
| Gene | MAPK3 |
| Organism | Homo sapiens |
| Length | 379 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (15)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (1200)
Diseases linked to this target (Open Targets).
- cancer · score 0.62
- Noonan syndrome · score 0.53
- hypertrophic cardiomyopathy · score 0.51
- Costello syndrome · score 0.50
- non-small cell lung carcinoma · score 0.39
- tuberculosis · score 0.38
- cardiofaciocutaneous syndrome · score 0.37
- neuroinflammatory disorder · score 0.34
- glioblastoma multiforme · score 0.33
- breast adenocarcinoma · score 0.30
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P27361-F1 | alphafold | PREDICTED | 87.98 | — |
Amino-acid sequence (379 residues)
MAAAAAQGGG GGEPRRTEGV GPGVPGEVEM VKGQPFDVGP RYTQLQYIGE GAYGMVSSAY DHVRKTRVAI KKISPFEHQT YCQRTLREIQ ILLRFRHENV IGIRDILRAS TLEAMRDVYI VQDLMETDLY KLLKSQQLSN DHICYFLYQI LRGLKYIHSA NVLHRDLKPS NLLINTTCDL KICDFGLARI ADPEHDHTGF LTEYVATRWY RAPEIMLNSK GYTKSIDIWS VGCILAEMLS NRPIFPGKHY LDQLNHILGI LGSPSQEDLN CIINMKARNY LQSLPSKTKV AWAKLFPKSD SKALDLLDRM LTFNPNKRIT VEEALAHPYL EQYYDPTDEP VAEEPFTFAM ELDDLPKERL KELIFQETAR FQPGVLEAP
Explore Mitogen-activated protein kinase 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets